Posted in Flagyl on February 26, 2015

Actavis plc (ACT – Analyst Report) accepted positive news on the regulatory face with the FDA approving Avycaz for the treatment of adults suffering from complicated intra-ventral infections (cIAI) (in combination with metronidazole) and complicated urinary pamphlet infections (cUTI) including pyelonephritis caused ~ the agency of designated susceptible bacteria, including certain enterobacteriaceae and pseudomonas aeruginosa.

However, Actavis mentioned that Avycaz should simply be used by patients who possess limited or no alternative treatment options.

We official communication that Avycaz, being a qualified pestiferous disease product, enjoys a five-year regulatory dilatation of exclusivity under the Hatch-Waxman Act.

Avycaz decree be available from the second lodge of 2015.

Our Take

We continue optimistic about Actavis’ growth prospects. We are decisive on the Forest acquisition which is in draw with Actavis’ strategy of building its branded outcome portfolio. Meanwhile, the Durata acquisition has boosted Actavis’ infectious disease portfolio. The upcoming Allergan (AGN – Analyst Report) acquisition furthermore looks good to us. We are encouraged by Actavis’ focus on building its branded and biosimilars pipeline.

Actavis intends to adopt Allergan similar to its corporate name once the acquisition goes end. With this acquisition, Actavis, which was antecedently known for its strong presence in the generics emporium, will find itself in the circle of the top 10 pharmaceutical companies transversely the world based on sales.

Actavis, that reported impressive fourth quarter results recently, provided a strong stand-alone outlook for 2015.

Actavis carries a Zacks Rank #2 (Buy). Some taker of odds-ranked stocks in the health care sector contain Cambrex Corporation (CBM – Snapshot Report) and BioMarin Pharmaceutical Inc (BMRN – Analyst Report). Both gripe a Zacks Rank #1 (Strong Buy).

North America and Europe being of the kind which the number of people who bear up the bacterium Helicobacter pylori has declined.